Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D05MJU
|
||||
| Former ID |
DNC000072
|
||||
| Drug Name |
4-iodobenzo[b]thiophene 2-carboxamidine
|
||||
| Drug Type |
Small molecular drug
|
||||
| Indication | Discovery agent | Investigative | [534982] | ||
| Formula |
C9H8IN2S+
|
||||
| Canonical SMILES |
C1=CC2=C(C=C(S2)C(=[NH2+])N)C(=C1)I
|
||||
| InChI |
1S/C9H7IN2S/c10-6-2-1-3-7-5(6)4-8(13-7)9(11)12/h1-4H,(H3,11,12)/p+1
|
||||
| InChIKey |
YERQOXAYAFWFEJ-UHFFFAOYSA-O
|
||||
| CAS Number |
CAS 13922-04-8
|
||||
| PubChem Compound ID | |||||
| PubChem Substance ID | |||||
| SuperDrug ATC ID |
L01XX16
|
||||
| SuperDrug CAS ID |
cas=000459869
|
||||
| Target and Pathway | |||||
| Target(s) | Urokinase-type plasminogen activator | Target Info | Inhibitor | [534982] | |
| NetPath Pathway | IL2 Signaling Pathway | ||||
| EGFR1 Signaling Pathway | |||||
| Pathway Interaction Database | Beta1 integrin cell surface interactions | ||||
| E2F transcription factor network | |||||
| Beta3 integrin cell surface interactions | |||||
| Osteopontin-mediated events | |||||
| Validated transcriptional targets of AP1 family members Fra1 and Fra2 | |||||
| amb2 Integrin signaling | |||||
| ATF-2 transcription factor network | |||||
| AP-1 transcription factor network | |||||
| Beta2 integrin cell surface interactions | |||||
| Urokinase-type plasminogen activator (uPA) and uPAR-mediated signaling | |||||
| Beta5 beta6 beta7 and beta8 integrin cell surface interactions | |||||
| FGF signaling pathway | |||||
| Reactome | Dissolution of Fibrin Clot | ||||
| References | |||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Tang and Dr. Zhang.